ABSTRACT
With high levels of the Delta variant of COVID-19 circulating in England during September 2021, schools are set to reopen with few school-based non-pharmaceutical interventions (NPIs). In this paper, we present simulation results obtained from the individual-based model, JUNE, for school opening after a prior vaccination campaign using an optimistic set of assumptions about vaccine efficacy and the likelihood of prior-reinfection. We take a scenario-based approach to modelling potential interventions to assess relative changes rather than real-world forecasts. Specifically, we assess the effects of vaccinating those aged 16-17, those aged 12-17, and not vaccinating children at all relative to only vaccinating the adult population. Vaccinating children in the 12-15 age group would have had a significant impact on the course of the epidemic, saving thousands of lives overall in these simulations. In the absence of such a vaccination campaign our simulations show there could still be a significant positive impact on the epidemic (fewer cases, fewer deaths) by continuing NPI strategies in schools. Our analysis suggests that the best results are likely derived from a combination of vaccinations and NPIs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
t. J.A.B., C.C.L., A.Q.B. thank the STFC-CDT DDIS for their support throughgrant ST/P006744/1. F.K. gratefully acknowledges funding as a Royal Society Wolfson Research Fellow. We gratefullyacknowledge the generous provision of computing time on the Hartree and JASMIN facilities. The bulk of this work usedthe DiRAC@Durham facility managed by the Institute for Computational Cosmology on behalf of the STFC DiRAC HPC Facility (www.dirac.ac.uk). The equipment was funded by BEIS capital funding via STFC capital grants ST/K00042X/1,ST/P002293/1, ST/R002371/1 and ST/S002502/1, Durham University and STFC operations grant ST/R000832/1. DiRAC,Hartree and JASMIN are part of the National e-Infrastructure.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics approval was not required for this study as the data we use is open. We use the Health Research Authority (HRA)decision tool and consulted HRA formally who provided formal acknowledgment of our exemption.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* carolina.cuesta-lazaro{at}durham.ac.uk, frank.krauss{at}durham.ac.uk
Data Availability
Data will be made availble on Zenodo or a similar repository before publication.